Incannex Healthcare Inc, the soon-to-be parent company of Incannex Australia Ltd, plans to appoint Computershare Trust Company, N.A. as its US transfer agent and registrar following the implementation of its schemes of arrangement.
The proposed scheme involves redomiciling Incannex Australia shares on the Nasdaq ahead of an ASX de-listing.
READ: Incannex Healthcare moves to delist from ASX and shift shares to Nasdaq in plan to redomicile to US
The schemes of arrangement have been approved by security holders and the Australian federal court, enabling the share transfer.
Incannex Australia shareholders have been advised to open an online account with Computershare to facilitate the transfer and to obtain technical and management support throughout the transition period.
A dedicated telephone hotline has also been established to troubleshoot any account opening or management issue that may arise.
About the company
Incannex is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea, traumatic brain injury and concussion, lung inflammation, rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
It has a strong patent filing strategy in place and holds 20 granted patents and over 30 pending patent applications.